Acquisition by Revolution Medicines of Warp Drive Bio, a developer of genomic technology to discover drugs of natural origin. Financial terms were not disclosed. “The merged R&D portfolio represents a rich pipeline of near- and long-term development opportunities for our R&D team to advance in support of our continuing commitment to translate frontier oncology targets on behalf of cancer patients,” said Mark A. Goldsmith, M.D., Ph.D., president and chief executive officer of REVOLUTION Medicines. “We appreciate the groundbreaking research by Warp Drive Bio scientists that inspired this deal. The synergistic combination of capabilities and assets will deepen our ability to target cancer drivers precisely and comprehensively and will accelerate our trajectory as a leading oncology company.”